Shield Therapeutics plc, a specialty pharmaceutical company, focuses on the development and commercialization of secondary care-focused pharmaceuticals. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its first pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 and PT40 intravenous iron formulations. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolLON:STX
CUSIPN/A
Phone+44-191-5118500
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-6,780.28%
Return on Equity-38.71%
Return on Assets-36.22%
Miscellaneous
EmployeesN/A
Outstanding Shares116,430,000
Shield Therapeutics (LON:STX) Frequently Asked Questions
What is Shield Therapeutics' stock symbol?
Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."
What price target have analysts set for STX?
1 equities research analysts have issued 12-month price targets for Shield Therapeutics' shares. Their forecasts range from GBX 220 to GBX 265. On average, they expect Shield Therapeutics' stock price to reach GBX 243.33 in the next twelve months. View Analyst Ratings for Shield Therapeutics.
Who are some of Shield Therapeutics' key competitors?
Some companies that are related to Shield Therapeutics include Cipher Pharmaceuticals (CPHRF), Marijuana Company Of America (MCOA), Amryt Pharma (AMYT), Acerus Pharmaceuticals (ASP), Indiva (NDVA), Science in Sport (SIS), CV Sciences (CVSI), Aequus Pharmaceuticals (AQS), EVIO (EVIO), Evgen Pharma (EVG), Venture Life Group (VLG), ESSA Pharma (EPI), Mountain High Acquisitions (MYHI), Lattice Biologics (LBL) and Premier Biomedical (BIEI).
Who are Shield Therapeutics' key executives?
Shield Therapeutics' management team includes the folowing people:
- Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 50)
- Dr. Karl Keegan BSc, MPhil, Ph.D., MSc, Interim Chief Financial Officer (Age 51)
- Fleur Wood, Director of Investor Relations
- Ms. Suzanne Wood, Group HR Director
- Mr. Paul Steckler, Chief Commercial Officer
Has Shield Therapeutics been receiving favorable news coverage?
News coverage about STX stock has trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Shield Therapeutics earned a news sentiment score of 0.08 on Accern's scale. They also gave media coverage about the company an impact score of 45.95 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Shield Therapeutics?
Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Shield Therapeutics' stock price today?
One share of STX stock can currently be purchased for approximately GBX 38.50.
How big of a company is Shield Therapeutics?
Shield Therapeutics has a market capitalization of £20.52 million.
How can I contact Shield Therapeutics?
Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500.
MarketBeat Community Rating for Shield Therapeutics (STX)
MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote "Outperform" if you believe STX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STX will underperform the S&P 500 over the long term. You may vote once every thirty days.
